AXA Framlington Biotech Fund GBP Z Acc
|Amgen Inc||7.82 %|
|Biogen Inc||7.09 %|
|Regeneron Pharmaceuticals Inc||6.45 %|
|Gilead Sciences Inc||6.07 %|
|Alexion Pharmaceuticals Inc||4.80 %|
|Vertex Pharmaceuticals Inc||4.52 %|
|Seattle Genetics Inc||3.72 %|
|Incyte Corp||3.70 %|
|Biomarin Pharmaceutical Inc||2.95 %|
|Alnylam Pharmaceuticals Inc||2.90 %|
|United States||89.25 %|
Dani Saurymper joined AXA IM in April 2015 as Fund Manager for the AXA Framlington Health Fund. He joined from Barclays Capital where he was a senior equity research analyst covering European healthcare.
Data provided by Morningstar.
The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.
This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.
You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.